Cyclopamine (Veratrum Steroidal Alkaloid · Hedgehog Pathway · SMO Inhibitor · Teratogen)

Compound	Cyclopamine (11-Deoxojervine)
Chemical class	Alkaloid — Steroidal Alkaloid (Jervanine-type; Veratrum isosteroidal)
CAS	4449-51-8
Primary source	Veratrum californicum (California corn lily, false hellebore)
Key applications	Hedgehog signalling pathway inhibitor (oncology research); teratogenic; informational only
Claim strength	Moderate (research context only)
Typical form	Research chemical; pharmaceutical oncology investigational compound; not a supplement ingredient
Buy from Herbuno	Browse HerbIQ Compound Index →

Name origin: Cyclopamine was named after the cyclops lambs born to ewes that had grazed on Veratrum californicum during early pregnancy — one of the most striking teratological observations in veterinary medicine. The facial malformation (holoprosencephaly, cyclopia) resulted from cyclopamine inhibiting Sonic Hedgehog (SHH) signalling during embryonic development. Cyclopamine is 11-deoxojervine — the deoxy analogue of jervine, the primary teratogenic alkaloid of Veratrum californicum. Historical discovery: The cyclopamine story is a remarkable example of veterinary teratology leading to a major scientific discovery. From the 1950s, US Sheep Experiment Station researchers in Idaho investigated cyclops lambs born to ewes grazing in high-altitude corn lily (Veratrum californicum) fields. Over 20 years of research (Keeler, 1960s–1980s) identified jervine and cyclopamine as the responsible compounds and their timing window (gestation days 10–15 in sheep) — work that eventually led to the discovery of the Sonic Hedgehog signalling pathway’s role in embryonic development and its later exploitation as an oncology drug target. Research and pharmaceutical context: The identification that cyclopamine inhibits the Hedgehog pathway (via direct SMO inhibitor binding) transformed the scientific understanding of Hedgehog signalling in cancer. Hedgehog-driven cancers (basal cell carcinoma, medulloblastoma, small cell lung cancer) are now treated with SMO inhibitors (vismodegib, sonidegib — synthetic drugs developed from the cyclopamine lead). Cyclopamine itself is too teratogenic and has limited bioavailability for pharmaceutical use, but it remains the foundational research tool for Hedgehog pathway biology. Supplement status: Cyclopamine is extremely teratogenic, not commercially available as a supplement, and has no safe dosing window for human use.

---

Cyclopamine — Scientific Significance

Sonic Hedgehog pathway inhibition — foundational mechanism: Cyclopamine binds directly to Smoothened (SMO) — a key signalling protein in the Hedgehog pathway — inhibiting Hedgehog signal transduction with nanomolar potency. The Hedgehog pathway regulates embryonic development and, when aberrantly activated in adults, drives proliferation in multiple cancer types. Cyclopamine’s identification as an SMO inhibitor opened the entire field of Hedgehog pathway oncology and directly led to the development of vismodegib (FDA-approved 2012 for BCC) and sonidegib (FDA-approved 2015 for BCC). Scientific significance: High; supplement claim relevance: None.

Teratogenicity — cyclopia and holoprosencephaly: Cyclopamine and jervine inhibit Hedgehog signalling during critical embryonic development windows, blocking midline fusion of the forebrain and facial development — producing cyclopia (single median eye), holoprosencephaly, and other severe craniofacial malformations. Sheep gestation days 10–15 are the critical window; the human developmental equivalent timing is the fourth to sixth week of pregnancy. This represents one of the most potent naturally occurring teratogens known. Critical safety information.

---

Frequently Asked Questions — Cyclopamine

How did cyclopamine lead to cancer drugs?
The mechanistic investigation of cyclopamine-induced cyclopia in lambs led to the discovery that cyclopamine targets the Sonic Hedgehog pathway — first by Philip Beachy’s group (Stanford, 1998) who identified cyclopamine’s SMO binding. This finding led to high-throughput drug screens for synthetic SMO inhibitors with better bioavailability and less teratogenicity — producing vismodegib and sonidegib, now standard treatments for advanced BCC. Cyclopamine is thus both a major oncology drug discovery starting point and one of the most significant examples of veterinary teratology informing human pharmacology.

Are Veratrum species used in traditional medicine?
Yes — with extreme caution. Veratrum album (white hellebore) and Veratrum nigrum (black false hellebore) have been used in European, Chinese (Li Lu), and Ayurvedic traditional medicine in very small doses for specific conditions (hypertension, emetic preparations, parasiticides). The narrow therapeutic/toxic margin and teratogenic risk make modern Veratrum preparations extremely high-risk. No regulatory approval exists for Veratrum supplement preparations in Western markets.

What is the difference between cyclopamine, jervine, and veratramine?
All three are steroidal alkaloids from Veratrum californicum: jervine (primary teratogen, 11-ketone) → cyclopamine (11-deoxojervine, deoxy form) → veratramine (non-teratogenic, reduced form). Jervine is the most teratogenic; cyclopamine is the most potent SMO inhibitor for Hedgehog research; veratramine is less teratogenic but highly toxic via cardiovascular depression (hypotension, bradycardia).

Is there any safe botanical preparation containing Veratrum alkaloids?
No — all commercial Veratrum alkaloid preparations (veratrum-containing herbal products) carry significant toxicity risks. No Veratrum supplement should be sold in Western markets. The historical pharmaceutical veratrum preparations (Veriloid, Unitensen) for hypertension were withdrawn from use due to the narrow therapeutic index and availability of safer antihypertensives. Traditional TCM Li Lu (Veratrum nigrum) preparations require trained practitioner supervision and are not appropriate for commercial supplement products.

Related compounds: Jervine, Veratramine, Colchicine, Taxol

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery